The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.
FDA Greenlights Companion Diagnostic for Mobocertinib in EGFR Exon 20 Insertion+ NSCLCSeptember 16th 2021
The FDA has granted premarket approval to the Oncomine Dx Target Test for use as a companion diagnostic to identify patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations who may be eligible to receive the newly approved small molecule TKI mobocertinib.
ESMO Publishes Guidelines for the Management of Solid Tumor Brain MetastasesSeptember 7th 2021
The European Association of Neuro-Oncology and ESMO have released clinical practice guidelines, which provide management recommendations for the diagnosis, treatment, and follow-up of patients with solid tumor brain metastases.
Genomic-Adjusted Radiation Dose Is Associated With First Recurrence and Survival in Solid TumorsSeptember 3rd 2021
Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.
Increasing Use of Molecular Assays Will Help With Accurate NSCLC Diagnoses, Treatment PlansAugust 18th 2021
Overall survival was significantly improved at 18.6 months in patients with non–small cell lung cancer who received targeted therapy compared with those who did not receive targeted therapy at 11.4 months, according to a pooled analysis of patients who received National Comprehensive Cancer Network-guided therapies in accordance with their biomarkers.
FDA Green Lights First Companion Diagnostic for Dostarlimab in dMMR Solid TumorsAugust 18th 2021
The FDA has approved the VENTANA MMR RxDx panel as the first companion diagnostic test to assist in identifying patients with solid tumors that are DNA mismatch repair deficient who may be eligible to receive the anti–PD-1 therapy dostarlimab-gxly, which was recently granted an accelerated approval by the agency.
CEACAM5 Joins a Growing Menu of Emerging Lung Cancer TargetsAugust 3rd 2021
After nearly two decades of successfully developing therapies directed at molecular aberrations in non–small cell lung cancer, investigators are exploring a new generation of novel targets, including some not specifically associated with driver mutations.
FDA Approves FoundationOne Liquid CDx as Companion Diagnostic for Capmatinib in METex14+ NSCLCJuly 16th 2021
The FDA has approved the FoundationOne Liquid CDx for use as a companion diagnostic to assist in the identification of patients with metastatic non–small cell lung cancer whose tumors harbor MET exon 14 skipping mutations and who could derive benefit from treatment with capmatinib.
Persistent Development of WEE1 Pathway Inhibitors Begins to Pay OffJuly 16th 2021
The lead novel candidate, the WEE1 inhibitor adavosertib, has been tested in more than 50 completed or ongoing clinical studies but has yet to proceed to a phase 3 trial despite showing promising safety and efficacy as monotherapy and in combination with a range of other cancer therapies.
Emerging Immune Checkpoint Research Focuses on CD137July 8th 2021
During the past decade, a growing number of PD-1/PD-L1 inhibitors gained FDA approval to treat a wide range of cancer types. Their stimulatory counterparts also emerged as sought-after anticancer targets but have proved much more challenging to manipulate therapeutically.
FDA Gives Green Light to Companion Diagnostic for Brigatinib in ALK+ NSCLCJuly 1st 2021
The FDA has approved FoundationOne CDx for use as a companion diagnostic for brigatinib, which was approved for the treatment of adult patients with ALK-positive, metastatic non–small cell lung cancer.
NRG1 Fusions Confer Low PD-L1, Low TMB, and Limited Immunotherapy Responses in Lung CancerJune 30th 2021
NRG1 fusions, which are often first detected by RNA-based sequencing, confer a more molecularly, pathologically, and clinically diverse subtype of lung cancer compared with historical hypotheses.
Using NGS to Inform More Than Diagnosis in Myeloid MalignanciesJune 29th 2021
Next-generation sequencing plays a critical role in the diagnosis of patients with myeloid malignancies, but it also plays a necessary role in the identification of passenger mutations and subclonal events that go beyond founding drivers.
Integration of Clinical Data With Diagnostic Genome Profiling May Produce Personalized Prognostic Predictions in MDSJune 21st 2021
Several distinct subgroups have been identified within the myelodysplastic syndrome genomic landscape and have notable clinical features and discrete evolution patterns that provide proof of concept for next-generation disease classification and prognosis.
KRAS Pathway Opens Door for Patients With Difficult-to-Treat Ovarian CancerJune 18th 2021
Dual blockade of the RAF/MEK and FAK pathways presents an opportunity for investigators to enhance and expand the number of patients with recurrent low-grade serous ovarian cancer who can benefit from targeted therapies.